Discover investment opportunities in Best Stocks Under $1 To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks Under $1 To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks Under $1 To Buy using our Smart AI Filter.
5 stocks found for "Best Stocks Under $1 To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.36 | ±100.0% | -0.2 | 0.00% | |||
0.52 | ±84.5% | -2.2 | 0.00% | |||
0.82 | ±100.0% | -0.3 | 0.00% | |||
1.18 | ±100.0% | -1.1 | 0.00% | |||
0.68 | ±100.0% | -14.3 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer. The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
Read moreQ: What are the potential benefits of investing in PSTV?
A: Plus Therapeutics, Inc. (PSTV) focuses on oncology treatments, offering investors exposure to the biotech sector. Its clinical-stage programs may appeal to those seeking growth opportunities, though the outcomes are uncertain due to clinical trial risks.
Q: How does RNAZ fit within the biotech investment sphere?
A: TransCode Therapeutics, Inc. (RNAZ) is involved in RNA-based cancer therapies, tapping into a growing segment of biotech. Investors might consider its pioneering approach, but should also be aware of the high research and regulatory risks.
Q: What is unique about ADXS as a penny stock investment?
A: Advaxis, Inc. (ADXS) is developing immunotherapies targeting various cancers. The company's innovation in immunotherapy could be attractive, though as a penny stock, it may entail high volatility and risk.
Q: Why might someone consider investing in TNXP?
A: Tonix Pharmaceuticals Holding Corp. (TNXP) develops therapies for central nervous system disorders. Investors looking for biotech growth might find its focus engaging, balanced against early-stage development uncertainties.
Q: What are the risks of investing in SONN?
A: Sonnet BioTherapeutics Holdings, Inc. (SONN) works on biologic medicines for cancer, bearing biotech sector volatility. As an emerging company, it carries high investment risk with potential upside in successful trials.
Q: What opportunities does REED present to investors?
A: Reed's Inc. (REED) produces craft beverages, offering an alternative play outside pure biotech. While potentially benefiting from consumer health trends, investors should consider the challenges in scaling and competition with large players.